Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Rises By 22.8%

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD - Get Free Report) was the target of a large growth in short interest in September. As of September 15th, there was short interest totalling 19,400 shares, a growth of 22.8% from the August 31st total of 15,800 shares. Approximately 3.4% of the company's stock are short sold. Based on an average daily volume of 25,600 shares, the short-interest ratio is presently 0.8 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "buy" rating and set a $0.20 price target on shares of Cadrenal Therapeutics in a research report on Thursday, June 6th.

Cadrenal Therapeutics Stock Performance

NASDAQ CVKD traded down $0.85 during trading hours on Monday, reaching $13.65. 42,262 shares of the company were exchanged, compared to its average volume of 22,525. The company has a market capitalization of $218.51 million, a PE ratio of -47.39 and a beta of 1.74. Cadrenal Therapeutics has a 1 year low of $5.40 and a 1 year high of $32.55.

Cadrenal Therapeutics (NASDAQ:CVKD - Get Free Report) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($2.25) EPS for the quarter, topping analysts' consensus estimates of ($19.04) by $16.79. As a group, analysts forecast that Cadrenal Therapeutics will post -6.72 EPS for the current fiscal year.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.